Amarin’s (NASDAQ:AMRN) bid to revive patents on heart treatment Vascepa has failed, with a U.S. Court of Appeals – just one day after hearing arguments – has affirmed the previous trial court ruling.
Jefferies says the Rule 36 judgement makes the odds about zero that the ruling can be appealed for en banc review or to the Supreme Court.
https://seekingalpha.com/news/3611464-amarin-loses-appeals-court-ruling-on-vascepa
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.